PR is also out of his depth. In saying that, PR is more...

PR is also out of his depth. In saying that, PR is more knowledgeable and experienced with repurposed treatments, Marco with generics. Marco has vastly more experience negotiating partnerships and licensing deals, albeit for generics.

PAR will rely heavily on consultants like most early stage biopharma companies do. IND and clinical trial execution is irrelevant right now since the entire program is underway. The pathway to NDA is clear, although you're right to say the board lacks specialised expertise in this domain, particularly for negotiating partnerships.

I am intrigued (like most) as to why Marco is standing down and the 3 months notice given as opposed to 6 months. Hopefully we will get more of an explanation soon.